Gastroenterology

Pancreatitis

63

Pipeline Programs↗

19

Active Trials↗

24

Companies Involved↗

Pancreatitis is a moderately active landscape with 63 programs across 24 companies. The most active players are AstraZeneca, Bayer, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 17 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

32/100

Mech. Concentration

18/100

Completion Rate

72/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

AstraZeneca

3 programs

Bayer

2 programs

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Kenvue Brands

1 program

Pfizer

1 program

Fresenius Kabi Oncology Ltd.

1 program

Pipeline

Programs by Phase

Preclinical17

Epinephrine

Samson Clinical Operations Pty Ltd

Aprepitant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Iohexol

GE Healthcare

Allopurinol

Alnylam Pharmaceuticals

Isosorbide Dinitrate

AstraZeneca

Phase 15

Amlodipine

Viatris Specialty LLC

Diclofenac Hydroxyethylpyrrolidine

Western Galilee Hospital-Nahariya

Lovaza

AstraZeneca

Aprotinin

Bayer

Epanova

AstraZeneca

Phase 29

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Ibuprofen

Kenvue Brands

Opioid

Johnson & Johnson

Parecoxib Sodium

Pfizer

DP-B99

D-Pharm Ltd.

Phase 315

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Duloxetine

Alnylam Pharmaceuticals

Tacrolimus

Veloxis Pharmaceuticals

Standard Dose Indomethacin

Indiana University

Simvastatin

Organon and Co

Approved17

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Doripenem

Shionogi

Pirfenidone

Legacy Health System

Diclofenac

Novartis

Indomethacin

Life Extension Foundation Inc.

Analysis

Trial Status

79

clinical trials

Completed36 · 46%

Terminated12 · 15%

Unknown status10 · 13%

Recruiting10 · 13%

Not yet recruiting8 · 10%

Withdrawn2 · 3%

Other1 · 1%

Clinical Trials

Trial Activity

79 trials

Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis

Recruiting·NNational Cheng-Kung University Hospital·Phase 4·NCT07083063·440 enrolled

Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Recruiting·TTanta University·Phase 3·NCT06860984·44 enrolled

Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis

Recruiting·—·Phase 3·NCT03713879·1,734 enrolled

Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis

Recruiting·—·Phase 4·NCT07088757·1,366 enrolled

Evaluation of the Benefit of Lidocaine on the Prevention of the Risk of Post Endoscopic Retrograde Cholangio-pancreatography Pancreatitis.

Recruiting·GGCS Ramsay Santé pour l'Enseignement et la Recherche·N/A·NCT05667987·1,800 enrolled

Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis

Recruiting·JJohns Hopkins University·Phase 3·NCT05252754·4,874 enrolled

Corticosteroids to Treat Pancreatitis

Recruiting·—·Phase 2·NCT05160506·86 enrolled

Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Recruiting·TTanta University·Phase 3·NCT06861010·44 enrolled

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

Recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT04195347·42 enrolled

Organ Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis Undergoing Open Necrosectomy

Recruiting·—·N/A·NCT06380842·200 enrolled

Diclofenac for Prevention of Post-ERC Pancreatitis

Not yet recruiting·KKarolinska Institutet·Phase 2/3·NCT03595150·1,000 enrolled

Lactated Ringer's Solution to Prevent Post-ERCP Pancreatitis

Not yet recruiting·UUniversity of South Florida·N/A·NCT03215862·242 enrolled

PERT in Acute Necrotizing Pancreatitis

Not yet recruiting·—·Phase 3·NCT07211568·188 enrolled

Aggressive Intravenous Hydration With or Without Indometacin to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy

Not yet recruiting·—·N/A·NCT07202559·1,250 enrolled

Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis

Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT06623513·100 enrolled

Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)